IMPORTANCE Insurance billing claim databases represent a growing field of scientific inquiry within ophthalmology. Validating the accuracy of billing claim codes used during the care of diabetic retinopathy is a necessary precursor to fully understanding the underlying data and subsequent results of these types of studies.
T he relative ease in obtaining data on millions of patients make insurance billing claim databases an appealing source for scientific inquiry. However, verifying the accuracy of billing codes is a necessary precursor to conducting these types of studies. Specific to ophthalmology, numerous diagnostic billing codes, including those for diabetic retinopathy (DR), have already been deemed accurate. [1] [2] [3] [4] [5] [6] [7] Despite this verification, the codes for ancillary testing, therapeutic procedures, or medications used during the care of DR have yet to be validated. The aim of this study is to test the accuracy of these codes.
Methods
A retrospective medical record review was performed including 11 retina specialists across 3 practices (a university-based academic practice and 2 private practices). Patients were selected from a list of insured patients with DR from each practice (International Classification of Diseases, Ninth Revision codes 362.01-362.07) that had a clinical encounter between 2011 and 2013. Starting with the first visit (index date), every encounter for the subsequent 2 calendar years was then reviewed twice. The first data abstraction collected the billing data. This included all Current Procedural Terminology 4 codes for diagnostic testing and therapeutic procedures (with laterality), as well as the Healthcare Common Procedure Coding System for drugs used during each visit. The second data abstraction from the medical record included all demographic information (at time of index visit), diagnostic test reports, and procedure notes (including medications used). Diagnostic tests were only considered performed if a report was placed in the medical record. Data for this study were collected and analyzed from October 2015 to July 2016. The University of Pennsylvania's institutional review board approved this study, and a waiver of consent was granted. The billing and medical record data were then compared for the following codes of interest: intravitreal injection, focal laser, panretinal photocoagulation, subtenon injection, laterality of procedure, ranibizumab, bevacizumab, aflibercept, triamcinolone, dexamethasone implant, fundus photographs, fluorescein angiography, optical coherence tomography, and B-scan ultrasonography (see the eTable in the Supplement for all codes used in this study). For laterality, both the eye having the procedure and not having the procedure were counted because 2 possibilities for error could happen in the recording and billing of any procedure. The medical record documentation was considered the ground truth for the presence or absence of an event. The positive predictive value (PPV) and negative predictive value (NPV) of the billings claims data were the main outcomes of the study. Sensitivity and specificity were also calculated as secondary outcomes. All statistical analyses were performed with Stata version 14 (StataCorp).
Results
A total of 146 patients with DR representing 1072 encounters from 2011 to 2015 were included. Among these patients, the mean (SD) age was 60.3 (12.5) years, 49.3% were female (n = 72), 48.6% were white (n = 71), 37.0% were black (n = 54), 14.4% were other/mixed race (n = 21), and 18.5% had type 1 diabetes ((n = 27) and had a mean (SD) hemoglobin A 1C level of 7.7% (1.8) (to convert to proportion of total hemoglobin, multiply by 0.01). Medicare was the most common insurance provider (35.0%), with 9 other insurers represented, including Medicaid (11.1%). Table 1 shows the raw numbers for each of the categories in terms of positive agreement (both bill and medical record agree procedure was done), negative agreement (both bill and medical record agree procedure was not done), and areas of disagreement (ie, recorded in the medical record, but not in the billing data, or vice versa). Of encounters with procedures, 1114 opportunities occurred for laterality to be assessed. Procedures or therapies that had fewer than 20 instances of occurrence were considered low volume and, as such, have less confidence around the accuracy of their statistics. These included codes for B-scan ultrasonography, subtenon injections, aflibercept, triamcinolone, and dexamethasone implant. Table 2 demonstrates the accuracy of each specific code studied in the billing data. With the exception of B-scan ultrasonography (69.6%), all codes had at least an 89.5% PPV (range, 89.5%-100%). Similarly, all codes had a NPV of at least 88.6% (range, 88.6%-100%). Sensitivity for all codes was also high (range, 88.9%-100%), with the exception of subtenon injections (40%). Correspondingly, the specificity was also high for all codes (range, 97.2%-100%).
Discussion
Within this study focused on retina clinic patients, for each of the high-volume DR codes evaluated, the billing data accurately represented the medical record in all instances. Fewer data were able to be collected on the low-volume procedures, making predictions of accuracy more difficult. Only subtenon injections and B-scan ultrasonography did not have accuracy levels suitable for future research use. This study validates therapeutic codes used in the care of patients with DR as a reliable proxy for most procedures.
Although our focus was therapeutic codes used in DR, we chose to include all patients with DR. By not restricting study patients to only those who had a procedure, we limited selection bias and permitted the calculation of an accurate NPV.
Key Points
Question Do codes in administrative billing claims data accurately represent the medical record for procedures, therapies, and diagnostic testing used in the care of diabetic retinopathy?
Findings Among 146 patients included in this medical record review, nearly all codes used in the care of diabetic retinopathy had high positive and negative predictive values as well as high sensitivity and specificity.
Meaning These data suggest diagnostic, procedure, and therapeutic codes derived from insurance billing claims accurately reflect the medical record for patients with diabetic retinopathy.
Clearly, when performing administrative billing claims database studies, understanding the accuracy of the code being studied is paramount (via the PPV). Conversely, it can be just as important to know that when a code is not seen in the database, the likelihood of the procedure being performed but not captured is low (via the NPV). In statistical terms, sensitivity and specificity are considered constant, meaning their values are independent of the underlying prevalence of the population. This is in contrast to the PPV and NPV, whose calculation is directly related to the population prevalence. For this reason, we feel the PPV and NPV are stronger accuracy indicators than sensitivity and specificity. However, given we only studied patients from retina clinics, it is likely our calculated PPVs would decrease (and the NPVs would increase), if a broader patient population were studied with a lower prevalence of DR procedures.
Owing to our study's observation window, a paucity of data was generated on aflibercept (US Food and Drug Administration approved for diabetic macular edema in 2014). Others have demonstrated the accuracy of a code often depends largely on reimbursement rate. 6, [8] [9] [10] The general guideline is that the more a procedure reimburses, the more likely it will be accurately coded. 8, 9 This could easily apply to aflibercept, where the high upfront cost incentivizes health care professionals to not underbill it, yet conversely, fear of committing fraud also incentivizes to not overbill. Extrapolating these data to aflibercept warrants caution, but it would not be surprising to expect a larger study of aflibercept to have comparable results as the other anti-vascular endothelial growth factor agents seen here.
Limitations
This study has limitations that need to be considered when reviewing its results. First, because claims databases are typically created by insurers, only insured patients were included. Therefore, the accuracy of coding may not generalize to the uninsured. Additionally, recent reports have called into question how accurately the medical record reflects patient's symptoms. 11 Although possible, in comparison with patient symptoms, medical record accuracy is likely to be less of an issue for procedure billing because it is often documented in multiple areas within the record. Next, we only had access to electronic medical records for this study. It is unclear how codes in paper records would fare in a similarly designed study. Last, this study was limited to encounters from retinal physicians. Although 11 physicians contributed data, these results may not be indicative of other retina or other nonretina physicians who provide DR therapy.
Conclusions
These data suggest diagnostic, procedure, and therapeutic codes derived from insurance billing claims accurately reflect the medical record for patients with DR. Going forward, researchers may use these procedure codes with greater assurances that the claims data accurately represent the events of a medical encounter.
